mRNAワクチンと治療薬の世界市場-2025～2032年

mRNAワクチンと治療薬の世界市場は2024年に4億1,000万米ドルに達し、2032年には5億300万米ドルに達すると予測され、予測期間2025年のCAGRは9.0%で成長します。

mRNAワクチンと治療薬はバイオテクノロジーにおける画期的な進歩であり、広範囲の感染症、遺伝性疾患、がんに対する革新的な解決策を提供します。弱毒化または不活化したウイルス粒子を用いて免疫反応を引き起こす従来のワクチンとは異なり、mRNAワクチンは病原体を模倣したタンパク質を産生するよう細胞に指示することで免疫系を刺激します。

mRNAワクチンと治療薬市場は、COVID-19に対するmRNAベースのワクチン採用の増加や、慢性疾患や複雑な疾患の治療におけるmRNA技術の有望な可能性に後押しされ、急成長を遂げています。特定の病原体や疾病メカニズムに素早く適応し、それを標的とする能力を持つmRNAは、従来の治療法に比べて副作用の少ないワクチンや治療法を開発するための柔軟なプラットフォームを提供します。

市場力学：

促進要因と抑制要因

慢性疾患の増加

がん、心血管疾患、その他の自己免疫疾患などの慢性疾患の有病率の上昇は、mRNAワクチンと治療薬市場の成長を促進すると予想されます。がん罹患率の増加に対する意識の高まりとともに、ワクチンや治療薬に対する需要が高まっています。例えば、2022年の米国国立がん研究所によると、世界では約2,000万人の新規患者が発生し、970万人ががんに関連して死亡しています。2040年には、年間の新規がん患者数は2,990万人に、がん関連死は1,530万人に増加すると予想されています。

慢性疾患は世界のヘルスケアシステムに大きな負担をかけ続けているため、より効果的な治療法や予防法に対する需要は着実に高まっています。mRNA技術は、COVID-19ワクチンですでにその有効性が証明されており、がんやその他の慢性疾患のような症状に対する標的療法の開発に大きな期待が寄せられています。

細胞に特定のタンパク質を産生させるmRNAの能力を利用することで、研究者は病気の根本原因に対処するワクチンや治療薬を生み出し、副作用の少ない、より的を絞った治療を提供できる可能性があります。慢性疾患を管理するための高度で個別化されたアプローチに対するニーズの高まりが、mRNAベースの治療薬市場の拡大を後押ししており、現代医学で最も急成長している分野のひとつと位置づけられています。

代替ワクチンや治療薬との競合

代替技術との競合は、より安全で確立されたソリューションを提供する可能性があるため、mRNAワクチンと治療薬市場の成長を阻害する可能性があります。例えば、タンパク質サブユニットワクチン、ウイルスベクターを用いたワクチン、モノクローナル抗体などは、様々な治療において成功裏に使用されてきた代替プラットフォームであり、医療従事者や患者によっては、馴染みがあるため好まれる可能性があります。

また、これらの代替品は、安全性、保存要件、製造上の課題などに関する懸念が少なく、状況によってはより魅力的なものとなる可能性があります。その結果、mRNAベースの製品の市場シェアは、特にこれらの競合技術がより効率的で、費用対効果が高く、あるいは長期的に広く受け入れられると証明された場合、制限に直面する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 慢性疼痛疾患の罹患率の増加
  • 抑制要因
    • mRNAワクチンと治療薬に関連する合併症
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 予防ワクチン
• 治療ワクチン
• 治療薬

第7章 用途別

• がん
• 感染症
• 稀な遺伝性疾患
• その他

第8章 エンドユーザー別

• 病院・クリニック
• 調査組織
• 学術機関
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• AstraZeneca
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Pfizer Inc.
• Moderna, Inc.
• BioNTech SE.
• Arcturus Therapeutics, Inc.
• CureVac SE
• Sanofi
• etherna
• Similar data will be provided for each market player.
• Orna Therapeutics
  • パイプライン製品の説明
  • 製品の主要業績評価指標（KPI）
  • 主な活動
  • 市場参入のタイムライン
  • 製品普及率
  • 売上予測と予測
• ReCode Therapeutics
• 各市場参入企業に同様のデータが提供されます。

第12章 付録

第13章 米国問い合わせ

The global mRNA Vaccines and Therapeutics market reached US$ 410 million in 2024 and is expected to reach US$ 503 million by 2032, growing at a CAGR of 9.0% during the forecast period 2025-2032.

mRNA vaccines and therapeutics represent a groundbreaking advancement in biotechnology, offering innovative solutions for a wide range of infectious diseases, genetic disorders, and cancer. Unlike traditional vaccines, which use weakened or inactivated virus particles to trigger immune responses, mRNA vaccines work by instructing cells to produce a protein that mimics the pathogen, thereby stimulating the immune system.

The mRNA vaccines and therapeutics market has experienced rapid growth, fueled by the increased adoption of mRNA-based vaccines for COVID-19 and the promising potential of mRNA technology in treating chronic and complex diseases. With the ability to quickly adapt and target specific pathogens or disease mechanisms, mRNA offers a flexible platform for developing vaccines and therapies with fewer side effects compared to traditional treatments.

Market Dynamics: Drivers & Restraints

Growing cases of chronic diseases

The rising prevalence of chronic diseases such as cancer, cardiovascular diseases and other autoimmune diseases is expected to drive the mRNA vaccines and therapeutics market growth. There is a growing demand for vaccines and therapeutics with the growing awareness of the increasing incidence of cancer cases. For instance, according to the National Cancer Institute in 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million.

As chronic diseases continue to place a significant strain on global healthcare systems, the demand for more effective treatments and preventative solutions is steadily increasing. mRNA technology, which has already proven its effectiveness in COVID-19 vaccines, holds great promise for developing targeted therapies for conditions like cancer and other chronic illnesses.

By utilizing mRNA's ability to direct cells to produce specific proteins, researchers have the potential to create vaccines and therapeutics that address the root causes of diseases, offering more targeted treatments with fewer side effects. This growing need for advanced, personalized approaches to managing chronic diseases is driving the expansion of the mRNA-based therapeutics market, positioning it as one of the fastest-growing areas in modern medicine.

Competition from Alternative Vaccines and Therapeutics

Competition from alternative technologies could hinder the growth of the mRNA vaccines and therapeutics market by offering potentially safer or more established solutions. For instance, protein subunit vaccines, viral vector-based vaccines, and monoclonal antibodies are alternative platforms that have been used successfully in various treatments and may be preferred by some healthcare providers or patients due to their familiarity.

These alternatives may also present fewer concerns related to safety, storage requirements, or production challenges, making them more appealing in certain situations. As a result, the market share for mRNA-based products could face limitations, especially if these competing technologies prove more efficient, cost-effective, or widely accepted in the long run.

Segment Analysis

The global mRNA Vaccines and Therapeutics market is segmented based on product type, application, end-user, and region.

Type:

Prophylactic vaccines segment is expected to dominate the global mRNA vaccines and therapeutics market share

The prophylactic vaccines segment is poised to dominate the mRNA vaccines and therapeutics market, fueled by the proven success of mRNA technology in addressing infectious diseases, particularly with COVID-19 vaccines. The inherent speed and flexibility of mRNA platforms enable rapid development and scalable production, making them invaluable in responding to emerging health threats and pandemics. This capability has fostered strong confidence in mRNA vaccines, known for delivering robust, long-lasting immunity and their adaptability to new pathogens.

Beyond COVID-19, the development of mRNA vaccines for infectious diseases like influenza and HIV further positions this technology as a key solution for global health challenges. As the approval and widespread adoption of mRNA-based vaccines continue to expand, the prophylactic vaccines segment is set to maintain a dominant position in the market, driven by the technology's effectiveness and its potential to address a wide range of infectious diseases.

Geographical Analysis

North America is expected to hold a significant position in the global mRNA vaccines and therapeutics market share

North America is expected to hold a significant position in the global mRNA vaccines and therapeutics market due to several key factors. Several pharmaceutical companies and biotech firms have been at the forefront of mRNA vaccine development, especially in response to the COVID-19 pandemic. These companies' expertise, along with substantial investment in mRNA technology, has positioned North America as a global leader in both research and commercialization of mRNA-based therapies.

For instance, in May 2024, Moderna Inc. received the FDA approval for the mRNA RSV vaccine, which will be marketed as mRESVIA. The novel mRNA RSV vaccine is indicated to protect adults aged 60 years and older from lower respiratory tract disease (LRTD) caused by RSV infection. The approval was granted under a breakthrough therapy designation, marking Moderna's second FDA-approved mRNA vaccine.

Additionally, North America benefits from a robust regulatory framework, with agencies such as the U.S. FDA and Health Canada offering significant support in the approval and distribution of mRNA vaccines and therapeutics. This conducive regulatory environment accelerates the approval process, ensuring faster market access and allowing companies to introduce innovative treatments with greater efficiency.

Moreover, the region has robust funding and clinical organizations involved in the development of several vaccines and therapeutics. Several clinical trials are being conducted in the region by companies and organizations which increases the product portfolio and meets the rising demand for vaccines. For instance, in February 2023, Pfizer Inc. and BioNTech SE initiated Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies' mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicella-zoster virus (VZV). Shingles affects millions of people around the world each year.

In December 2022, Moderna, Inc. and Merck announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R), Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of recurrence-free survival (RFS) versus KEYTRUDA alone for the adjuvant treatment of patients with stage III/IV melanoma following complete resection.

Competitive Landscape

The major global players in the mRNA vaccines and therapeutics market include AstraZeneca, Pfizer Inc., Moderna, Inc., BioNTech SE., Arcturus Therapeutics, Inc., CureVac SE, Sanofi, and etherna among others.

Key Developments

• In September 2024, ME Therapeutics Holdings Inc. announced the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc.
• In April 2024, Sanofi signed a master service agreement with IDT Australia focusing on the preclinical formulation development and current Good Manufacturing Practice (cGMP) manufacturing of its messenger RNA (mRNA) vaccines.
• In April 2024, VBI Vaccines Inc. expanded its collaboration with the government of Canada, supported by a funding contribution from the government's Strategic Innovation Fund (SIF). Under the new agreement, the remaining CAD$28 million of funding available under the previously committed CAD$56 million will be directed toward the development of VBI's proprietary MLE platform, a next-generation version of the Company's particulate, enveloped virus-like particle ("eVLP") vaccine technology that enables the coding of eVLPs using messenger RNA ("mRNA").

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global MRNA Vaccines and Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of chronic pain conditions
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with mRNA Vaccines and Therapeutics
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Prophylactic Vaccines*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Therapeutic Vaccines
• 6.4. Therapeutic Drugs

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Cancer*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Infectious Diseases
• 7.4. Rare Genetic Diseases
• 7.5. Others

8. By End-user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 8.1.2. Market Attractiveness Index, By End-user
• 8.2. Hospitals & Clinics*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Research Organization
• 8.4. Academic Institutes
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. AstraZeneca*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Pfizer Inc.
• 11.3. Moderna, Inc.
• 11.4. BioNTech SE.
• 11.5. Arcturus Therapeutics, Inc.
• 11.6. CureVac SE
• 11.7. Sanofi
• 11.8. etherna
• Similar data will be provided for each market player.

Emerging Market Players

• 11.9. Orna Therapeutics*
  • 11.9.1. Pipeline Products Description
  • 11.9.2. Product Key Performance Indicators (KPIs)
  • 11.9.3. Key Activities
  • 11.9.4. Market Entry Timelines
  • 11.9.5. Product Penetration Rate
  • 11.9.6. Sales Estimation and Projections
• 11.10. ReCode Therapeutics
• Similar data will be provided for each market player

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services

13. Contact Us